Potential osteogenic property and shows accelerated fracture repairing. New bone formation at the fracture site is increased by ~40% in rats, Increases callus formation at only 1 mg/kg dose and restores trabecular microarchitecture at fractured site in normal male and female and osteopenic rats, Increases bone healing in male and female New Zealand white rabbits at a dose as low as 1.0 mg.kg-1.day-1
, It leads to accelerated fracture repair by BMP-2/Smad signaling pathway, Compound found safe in single dose toxicity studies in rodents and in 10 days DRF studies, Essential Safety Pharmacology and Regulatory Toxicity study (Rodents and Non-rodents -dog) in GLP as per schedule Y/ FDA is completed and no mortality/adverse effect was observed, No orally active drug available in market. FDA has approved rhBMP-2 bone graft for open tibial fractures but it has several side effects and is very expensive, S007-1500 synthesis is industrially acceptable five step process. It will be cost effective and easily affordable, Will enable return to active life much faster
Central Research Institute (CRI)
Acces sibility Controls